REAL world efficacy and safety analysis of pembrolizumab KEY truda

REAL world efficacy and safety analysis of pembrolizumab KEY truda - REAL-KEY trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045538

Enrollment

1000

Registered

2021-09-30

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All of the following conditions must be met. 1) Patients with non-small cell lung cancer who started treatment with Keytruda (pembrolizumab) between February 1 and June 30, 2017. (2) Patients with non-small cell lung cancer who agreed with the purpose of this study and received treatment at a facility that conducts post-marketing surveillance based on the "Ministerial Ordinance Partially Amending the Ministerial Ordinance on Standards for Post-marketing Surveillance of Pharmaceuticals (Ministry of Health and Welfare Ordinance No. 151 of 2000)

Exclusion criteria

Exclusion criteria: No special rules

Design outcomes

Primary

Measure	Time frame
1 year survival	—

Countries

Japan

Contacts

Public ContactHideki Terai

Keio University Hospital Clinical and Translational Research Center

ksoejima@keio.jp0333531211

Outcome results